Sensei Biotherapeutics, Inc. (SNSE) Dividend History

Company News

• VISTA Inhibitor Clinical Trials Drug Approval Insight - GlobeNewswire

  VISTA inhibitors are an emerging class of immunotherapeutic agents with significant potential in treating cancer and autoimmune diseases. Several companies are actively pursuing VISTA inhibitors, which offer a novel mechanism of action and broad applicability, but also face challenges such as complex development landscape and competition from existing therapies.

  GlobeNewswire Inc.

  Featured Companies: CRIS MRK
• Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

  BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, being held in New York, NY, on Thursday, June 6, 2024 at 8:30 a.m. ET.

  GlobeNewswire Inc.
• Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

  - Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity -

  GlobeNewswire Inc.
• Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

  - Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities -

  GlobeNewswire Inc.
• Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

  BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), will be presented in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 – June 4, 2024.

  GlobeNewswire Inc.